For the twelve months ended Sep 30, 2026, MiMedx Group Inc reported $303.73M of revenue and -$19.19M of net income.
MDXG revenueQ3 2026$62.28M
- Quarter YoY
- -45.2%
- QoQ
- -3.2%
- FY YoY
- +20.0%
- 5Y CAGR
- +11.0%
MDXG revenue was $62.28M in fiscal Q3 2026 (ended Sep 30, 2026), down 45.2% from a year earlier and down 3.2% from the prior quarter. For the full fiscal 2025 it was $418.63M, up 20.0% from fiscal 2024. Compound annual growth was +11.0% over 5 years. It rose in 6 of the last 9 fiscal years. Fiscal 2025 is the highest of the 11 fiscal years on file.
MDXG net incomeQ3 2026-$8.68M
- FY YoY
- +14.5%
- 10Y CAGR
- +5.1%
MDXG net income was -$8.68M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $16.75M a year earlier. For the full fiscal 2025 it was $48.58M, up 14.5% from fiscal 2024. Compound annual growth was +5.1% over 10 years.
MDXG EPSQ3 2026-$0.06
- FY YoY
- +14.3%
- 10Y CAGR
- +2.1%
MDXG diluted EPS was -$0.06 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0.11 a year earlier. For the full fiscal 2025 it was $0.32, up 14.3% from fiscal 2024. Compound annual growth was +2.1% over 10 years.
Source: XBRL data MiMedx Group Inc files with the SEC, latest filing dated Oct 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.